Subsequent Events (Tables)

6 Months Ended

Jun. 30, 2017

Subsequent Events [Abstract]

Subsequent Activities Related to IPO and Novartis' Concurrent Private Placement

The following table summarizes certain actual balance sheet data and pro forma balance sheet data to reflect the activities related to our IPO noted above and Novartis’ concurrent private placement, as of June 30, 2017 (in thousands):

	June 30, 2017			Pro Forma June 30, 2017
Cash and cash equivalents and short-term investments	$	118,668		$	302,382
Other current assets		3,939			2,052
Accounts payable and accrued expenses		3,608			2,998
Line of credit with Ionis Pharmaceuticals, Inc.		107,507			—
Convertible preferred stock		100,000			—
Common stock		—			67
Additional paid-in capital		64,059			453,936
Total stockholders’ equity (deficit)		(82,983	)		206,961